Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status

Inflammatory Bowel Diseases

Volumn 21, Issue 10, 2015, Pages 2327-2340

  Stallhofer, Johannes ^a   Friedrich, Matthias ^a,b   Konrad Zerna, Astrid ^a   Wetzke, Martin ^c   Lohse, Peter ^a   Glas, Jürgen ^b,d   Tillack Schreiber, Cornelia ^a   Schnitzler, Fabian ^a   Beigel, Florian ^a   Brand, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

24p3; biomarker; Crohn's disease; cytokine; disease activity; genetics; I kappa B zeta; IL 17; IL 22; IL23R; inflammatory bowel disease; lipocalin 2; neutrophil gelatinase associated lipocalin; siderocalin; Th17 cells; TNF ; ulcerative colitis

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23 RECEPTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR IKBZ; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; I KAPPA B; IL17A PROTEIN, HUMAN; IL23R PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-22; LCN2 PROTEIN, HUMAN; LIPOCALIN; NFKBIZ PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CELLULAR SECRETION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HT 29 CELL LINE; HUMAN; HUMAN CELL; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; ULCERATIVE COLITIS; UPREGULATION; ADOLESCENT; BLOOD; COLON; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NORMAL HUMAN; TH17 CELL; YOUNG ADULT;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; AGED; BIOMARKERS; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; EPITHELIAL CELLS; FEMALE; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; I-KAPPA B PROTEINS; INTERLEUKIN-17; INTERLEUKINS; LIPOCALINS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS; RECEPTORS, INTERLEUKIN; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; YOUNG ADULT;

EID: 84942278816     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000515     Document Type: Article

References (41)

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
2. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009;58:1152-1167.
3. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
4. Glas J, Stallhofer J, Ripke S, et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol. 2009;104:1737-1744.
5. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010; 42:332-337.
6. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28:454-467.
7. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203:2271-2279.
8. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817-1826 e1812.
9. Goetz DH, Holmes MA, Borregaard N, et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophoremediated iron acquisition. Mol Cell. 2002;10:1033-1043.
10. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432: 917-921.
11. Nielsen BS, Borregaard N, Bundgaard JR, et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut. 1996;38:414-420.
12. Raffatellu M, George MD, Akiyama Y, et al. Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host Microbe. 2009;5:476-486.
13. Karlsen JR, Borregaard N, Cowland JB. Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaBzeta but neither by C/EBP-beta nor C/EBP-delta. J Biol Chem. 2010;285: 14088-14100.
14. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
15. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
16. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
17. Glas J, Seiderer J, WetzkeM, et al. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One. 2007;2:e819.
18. Cowland JB, Muta T, Borregaard N. IL-1beta-specific up-regulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. J Immunol. 2006;176:5559-5566.
19. Harries AD, Fitzsimons E, Fifield R, et al. Platelet count: a simple measure of activity in Crohn's disease. Br Med J (clin Res Ed). 1983;286:1476.
20. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006; 314:1461-1463.
21. Sarra M, Pallone F, Macdonald TT, et al. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis. 2010;16:1808-1813.
22. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65-70.
23. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 2006; 290:G827-G838.
24. Seiderer J, Elben I, Diegelmann J, et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis. 2008;14:437-445.
25. Schmechel S, Konrad A, Diegelmann J, et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis. 2008;14:204-212.
26. Dambacher J, Beigel F, Zitzmann K, et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 2009;58:1207-1217.
27. Brand S, Olszak T, Beigel F, et al. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem. 2006;97:709-723.
28. Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol. 1999;94:2923-2928.
29. Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54:1012-1024.
30. Oikonomou KA, Kapsoritakis AN, Theodoridou C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol. 2012;47:519-530.
31. Yesil A, Gonen C, Senates E, et al. Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity. Dig Dis Sci. 2013;58:2587-2593.
32. Janas RM, Ochocinska A, Snitko R, et al. Neutrophil gelatinaseassociated lipocalin (NGAL) in blood in children with inflammatory bowel disease. J Gastroenterol Hepatol. 2014;29:1883-1889.
33. Ostvik AE, Granlund AV, Torp SH, et al. Expression of toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2. Clin Exp Immunol. 2013;173:502-511.
34. Bolignano D, Della Torre A, Lacquaniti A, et al. Neutrophil gelatinaseassociated lipocalin levels in patients with Crohn disease undergoing treatment with infliximab. J Investig Med. 2010;58:569-571.
35. de Bruyn M, Arijs I, Wollants WJ, et al. Neutrophil gelatinase b-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014;20:1198-1207.
36. Buisson A, Barnich N, Goutte M, et al. Sa1216 faecal lipocalin-2 as biomarker in the evaluation of Crohn's disease activity. Gastroenterology. 2014;146:S233.
37. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet. 2001;10:445-456.
38. Liu Z, Petersen R, Devireddy L. Impaired neutrophil function in 24p3 null mice contributes to enhanced susceptibility to bacterial infections. J Immunol. 2013;190:4692-4706.
39. Berger T, Togawa A, Duncan GS, et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2006;103: 1834-1839.
40. Cayatte C, Joyce-Shaikh B, Vega F, et al. Biomarkers of therapeutic response in the IL-23 pathway in inflammatory bowel disease. Clin Transl Gastroenterol. 2012;3:e10.
41. Diegelmann J, Czamara D, Le Bras E, et al. Intestinal DMBT1 expression is modulated by Crohn's disease-associated IL23R variants and by a DMBT1 variant which influences binding of the transcription factors CREB1 and ATF-2. PLoS One. 2013;8:e77773.